NCT02731313View on ClinicalTrials.gov

Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma

CompletedOBSERVATIONAL
Enrollment

420

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Gastric Cancer, Gastroesophageal Junction Cancer
Interventions
BIOLOGICAL

Trastuzumab

Trastuzumab was not administered in this study. This study informs future trastuzumab treatment decisions.

Trial Locations (19)

13273

Marseille

13385

Marseille

25030

Besançon

29609

Brest

33604

Pessac

34295

Montpellier

34298

Montpellier

35000

Rennes

38700

La Tronche

44093

Nantes

51092

Reims

59500

Douai

75571

Paris

75679

Paris

76031

Rouen

80054

Amiens

84130

Le Pontet

92104

Boulogne-Billancourt

92118

Clichy

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02731313 - Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma | Biotech Hunter | Biotech Hunter